<DOC>
	<DOCNO>NCT00028509</DOCNO>
	<brief_summary>RATIONALE : Assessing effect methotrexate brain function child may improve ability plan treatment decrease side effect . PURPOSE : Clinical trial compare brain function child previously treat methotrexate .</brief_summary>
	<brief_title>Brain Function Children Previously Treated Clinical Trials POG-9605 POG-9201</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence neuropsychological abnormality leukoencephalopathy child previously treat methotrexate protocol POG-9605 versus POG-9201 . OUTLINE : This multicenter study . More 3 year completion therapy , patient undergo 9 different test assess intelligence , memory , learning , attention , concentration , process information , functioning , visual-motor integration . Patients also undergo MRI head . PROJECTED ACCRUAL : A total 30-54 patient previously treat protocol POG-9201 accrued study . A total 60-108 patient previously treat protocol POG-9605 accrued study .</detailed_description>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously enrol POG9201 POG9605 Good prognosis NCI risk ( 9201 9605 stratum 1 ) Eligible therapeutic study Completed therapy 12/31/2000 No CNS3 diagnosis No relapsed disease PATIENT CHARACTERISTICS : Age : 1 9 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No Down syndrome PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>long-term effect secondary cancer therapy child</keyword>
</DOC>